
|Articles|June 11, 2008
Dry AMD trial doses first patient
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
Advertisement
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
The trial, to determine safety, tolerability and pharmacokinetics of the oral treatment, is a single-site, double-masked, placebo-controlled, single ascending-dose study treating healthy subjects.
ACU-02 reduces the accumulation of A2E, thereby interrupting the pathophysiology of AMD and preserving retinal cells.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Beyond anti-VEGF: The next wave in retinal therapy
2
Trehalose-hyaluronate combination aids tear film after eyelid surgery
3
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
4
ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe
5




















